MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3174/ajnr.a9260

Медицинская библиотека · AJNR. American journal of neuroradiology · 2026

[68Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker.

Vu Kellen Vo, Otis Hannah G, Brandmaier Andrew, Osborne Joseph R, Stieg Philip E, Ramakrishna Rohan R, Haghdel Arsalan, Kim Sean H, Liechty Benjamin, Rosen Kate, Beal Kathryn, Pannullo Susan C, Knisely Jonathan P S, Magge Rajiv S, Welch Mary, Iwamoto Fabio, Pan Peter C, Ivanidze Jana

СтатьяКлинический случайПеревод в очереди

Аннотация

Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A, is emerging as a promising therapy for high-grade meningioma, an aggressive central nervous system tumor with limited systemic treatment options. While clinical stabilization has been observed in prior trials, radiographic response on conventional MRI is often minimal, highlighting the need for alternative imaging biomarkers to monitor treatment effect. [68Ga]-DOTATATE is a somatostatin analog that binds with high affinity to somatostatin receptor 2, which is overexpressed in meningiomas. In this case series, we present 3 patients with World Health Organization grade 3 meningioma who underwent baseline and follow-up [68Ga]-DOTATATE PET imaging in the setting of bevacizumab therapy. All patients had biopsy-confirmed high-grade disease and demonstrated multifocal [68Ga]-DOTATATE-avid lesions at baseline. Across 12 lesions, 67% showed a reduction in maximum standardized uptake value (SUVmax) after therapy. In contrast, matched control patients who underwent serial [68Ga]-DOTATATE PET imaging without bevacizumab or other systemic therapy demonstrated no significant change in SUVmax. Linear mixed-effects modeling confirmed a significant treatment effect, with a 7.2-unit greater reduction in SUVmax in the bevacizumab-treated group than in controls (P = .01). Our findings raise the possibility that [68Ga]-DOTATATE PET may capture early biologic responses to antiangiogenic therapy not reflected by anatomic imaging alone, potentially reflecting changes in somatostatin receptor expression, tumor perfusion, or metabolic activity. This series suggests that [68Ga]-DOTATATE PET may serve as a noninvasive, biologically informative adjunct to conventional imaging and supports further investigation of its role as a molecular imaging biomarker of bevacizumab response in high-grade meningioma.

Для цитирования: Vu Kellen Vo, Otis Hannah G, Brandmaier Andrew, Osborne Joseph R, Stieg Philip E, Ramakrishna Rohan R, Haghdel Arsalan, Kim Sean H, Liechty Benjamin, Rosen Kate, Beal Kathryn, Pannullo Susan C, Knisely Jonathan P S, Magge Rajiv S, Welch Mary, Iwamoto Fabio, Pan Peter C, Ivanidze Jana. [68Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker.. AJNR. American journal of neuroradiology. 2026. DOI: 10.3174/ajnr.a9260.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.